Table 2.
Changes in C-peptide levels of the T1D subjects after treatment at 12 weeks.
| Patient No. | C-peptide (ng/ml) | Changes in C-peptide levels (ng/ml) |
|---|---|---|
| Group A: | ||
| 1 | 0.56 | ↑ 0.26 |
| 2 | 0.98 | ↑ 0.42 |
| 3 | 0.54 | ↑ 0.42 |
| 4 | 1.1 | ↑ 0.46 |
| 5 | 0.52 | ↑ 0.34 |
| 6 | 0.78 | ↑ 0.60 |
| Mean | 0.75 | ↑ 0.42 |
| (SD) | (0.24) | (0.12) |
| Group B | ||
| 7 | 0.25 | ↑ 0.24 |
| 8 | 0.11 | ↑ 0.10 |
| 9 | 0.28 | ↑ 0.27 |
| 10 | 0.43 | ↑ 0.42 |
| 11 | 0.11 | ↑ 0.10 |
| 12 | 0.12 | ↑ 0.11 |
| Mean | 0.22 | ↑ 0.21 |
| (SD) | (0.13) | (0.13) |
| Control Group | ||
| 13 | 0.41 | ↑ 0.04 |
| 14 | 0.38 | ↓ 0.17 |
| 15 | 0.35 | ↑ 0.05 |
| Mean | 0.38 | ↓ 0.03 |
| (SD) | (0.03) | (0.12) |
Levels of plasma C-peptide before treatment served as baseline for comparison. The level of C-peptide was increased (↑); the level of C-peptide was decreased (↓).